These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 36999945)

  • 1. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
    Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
    Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RPA3 promotes the proliferation, migration, and invasion of gliomas by activating the PI3K-AKT-mTOR pathway.
    Liang L; Zhao Z; Jin Q; Zhang S; Zhao Z; Li X
    Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):80-86. PubMed ID: 37571896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAPK-activated protein kinase 2 is associated with poor prognosis of glioma patients and immune inhibition in glioma.
    Sun J; Wu S; Zhao W; Xue S; Zhang L; Ren J
    Front Oncol; 2024; 14():1307992. PubMed ID: 38322416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinster homolog 2 reduces malignancies of glioblastoma via PTEN/PI3K/AKT pathway.
    Liang W; Liu M; Su Y; Wen Y; Wang L; Shan J; Zhao J; Xie K; Wang J
    IUBMB Life; 2024 Mar; 76(3):140-160. PubMed ID: 37728571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.
    Wang W; Shen T; Dong B; Creighton CJ; Meng Y; Zhou W; Shi Q; Zhou H; Zhang Y; Moore DD; Yang F
    J Clin Invest; 2019 Mar; 129(3):1015-1029. PubMed ID: 30688659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K/AKT/mTOR pathway.
    Wang Y; Zhang S; Zhao Z; Jin Q; Wang Z; Song Z; Liu L; Zhao Z
    Immunobiology; 2024 May; 229(3):152802. PubMed ID: 38569452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.
    Xu L; Duan H; Zou Y; Wang J; Liu H; Wang W; Zhu X; Chen J; Zhu C; Yin Z; Zhao X; Wang Q
    Phytomedicine; 2023 Jun; 114():154764. PubMed ID: 36963368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The atypical protein kinase RIOK3 contributes to glioma cell proliferation/survival, migration/invasion and the AKT/mTOR signaling pathway.
    Zhang T; Ji D; Wang P; Liang D; Jin L; Shi H; Liu X; Meng Q; Yu R; Gao S
    Cancer Lett; 2018 Feb; 415():151-163. PubMed ID: 29233656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA MAPK4 (circ-MAPK4) inhibits cell apoptosis via MAPK signaling pathway by sponging miR-125a-3p in gliomas.
    He J; Huang Z; He M; Liao J; Zhang Q; Wang S; Xie L; Ouyang L; Koeffler HP; Yin D; Liu A
    Mol Cancer; 2020 Jan; 19(1):17. PubMed ID: 31992303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RRAGB-mediated suppression of PI3K/AKT exerts anti-cancer role in glioblastoma.
    Li Q; Liu X; Mao J; Liu S; Hou B; Li K; Fang D
    Biochem Biophys Res Commun; 2023 Oct; 676():149-157. PubMed ID: 37517217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDRG1 promotes the proliferation and migration of GBM cells by the MEK/ERK/CD44 pathway.
    Sun J; Xu Y; Liu J; Cui H; Cao H; Ren J
    Cancer Sci; 2022 Feb; 113(2):500-516. PubMed ID: 34812552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GALNT12 is associated with the malignancy of glioma and promotes glioblastoma multiforme in vitro by activating Akt signaling.
    Zheng Y; Liang M; Wang B; Kang L; Yuan Y; Mao Y; Wang S
    Biochem Biophys Res Commun; 2022 Jun; 610():99-106. PubMed ID: 35461073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connective tissue growth factor as an unfavorable prognostic marker promotes the proliferation, migration, and invasion of gliomas.
    Song ZB; Yang HP; Xu AQ; Zhan ZM; Song Y; Li ZY
    Chin Med J (Engl); 2020 Mar; 133(6):670-678. PubMed ID: 32197031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
    Kim D; Kwon W; Park S; Kim W; Park JK; Han JE; Cho GJ; Yun S; Han SH; Kim MO; Ryoo ZY; Choi SK
    Life Sci; 2022 Jan; 288():120170. PubMed ID: 34826438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.